Quach, Bryan C. http://orcid.org/0000-0002-1094-3104
Bray, Michael J.
Gaddis, Nathan C.
Liu, Mengzhen http://orcid.org/0000-0001-6550-6959
Palviainen, Teemu http://orcid.org/0000-0002-7847-8384
Minica, Camelia C. http://orcid.org/0000-0001-7140-8167
Zellers, Stephanie http://orcid.org/0000-0001-8927-3483
Sherva, Richard
Aliev, Fazil http://orcid.org/0000-0001-8357-4699
Nothnagel, Michael
Young, Kendra A.
Marks, Jesse A. http://orcid.org/0000-0002-8159-3594
Young, Hannah http://orcid.org/0000-0002-4248-9612
Carnes, Megan U.
Guo, Yuelong http://orcid.org/0000-0003-1287-1906
Waldrop, Alex http://orcid.org/0000-0002-4502-7894
Sey, Nancy Y. A. http://orcid.org/0000-0001-8762-7401
Landi, Maria T. http://orcid.org/0000-0003-4507-329X
McNeil, Daniel W.
Drichel, Dmitriy http://orcid.org/0000-0001-5978-3458
Farrer, Lindsay A.
Markunas, Christina A.
Vink, Jacqueline M.
Hottenga, Jouke-Jan http://orcid.org/0000-0002-5668-2368
Iacono, William G.
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Saccone, Nancy L. http://orcid.org/0000-0002-4710-3926
Neale, Michael C.
Madden, Pamela
Rietschel, Marcella http://orcid.org/0000-0002-5236-6149
Marazita, Mary L. http://orcid.org/0000-0002-2648-2832
McGue, Matthew
Won, Hyejung http://orcid.org/0000-0003-3651-0566
Winterer, Georg
Grucza, Richard
Dick, Danielle M. http://orcid.org/0000-0002-1636-893X
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Caporaso, Neil E.
Baker, Timothy B.
Boomsma, Dorret I. http://orcid.org/0000-0002-7099-7972
Kaprio, Jaakko http://orcid.org/0000-0002-3716-2455
Hokanson, John E.
Vrieze, Scott http://orcid.org/0000-0003-3861-7930
Bierut, Laura J. http://orcid.org/0000-0002-9952-4810
Johnson, Eric O. http://orcid.org/0000-0002-8870-1949
Hancock, Dana B. http://orcid.org/0000-0003-2240-3604
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA042090)
Article History
Received: 21 January 2020
Accepted: 24 September 2020
First Online: 3 November 2020
Competing interests
: L.J.B. and the spouse of N.L.S. are listed as inventors on U.S. Patent 8,080,371, ‘Markers for Addiction’ covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Y.G. is an employee of GeneCentric Therapeutics. Although unrelated to this research, H.R.K. is an advisory board member for Dicerna and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor and Amygdala Neurosciences. H.R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. J.K. consulted for Pfizer in 2012–2015 on ND. The remaining authors declare no competing interests.